Deep Pharma Intelligence

Modern Technologies for Preclinical and Clinical Optimisation

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** -- two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets -- technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our dashboard to learn more:
platform.dkv.global/dashboards/ai-for-drug-discovery

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.

Modern Technologies for Preclinical and Clinical Optimisation:

This 40-page "Modern Technologies for Preclinical and Clinical Optimisation" report aims to provide a comprehensive overview of the current state of the 3D models development. The aim of this report is to provide insights into the diversity of possible *in vitro* 3D models, mechanisms of their development and potential use in drug development.

This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry.

The current release includes insights about **165 companies** that develop organoids, organ-on-a-chip technologies and lab-automation tools and **260 investors**.

Benefits of *in Vitro* Models: Financial Reason



This graph demonstrates drug development costs and candidates vs. time, with and without organoids.

DEEP PHARMA INTELLIGENCE

Deep Pharma Intelligence

Modern Technologies for Preclinical and Clinical Optimisation



Market at a Glance: Companies

Distribution of Companies by Country, %



Distribution of Companies by Category, %



The **vast majority** of companies that conduct preclinical and clinical optimisation services is located in **Europe** and accounts for **49%** of the whole range of analysed companies. The European region is followed by the United States, with the total companies amounting to **45.5%** of all companies in both regions.

The main domains in which companies are being conducted are **Organoids**, **Lab automation**, **Organ-on-a-chip**, and **Microfluidics**, which account for **36.47%**, **30%**, **26.47%**, and **7.06%** of all companies, **respectively**.